肝細胞癌に対する分子標的薬および免疫療法の最新情報

抄録

Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib. Despite many attempts to develop new drugs after sorafenib, many clinical trials failed. Finally, 4 drugs (lenvatinib as a first-line agent and regorafenib, cabozantinib, and ramucirumab as second-line agents) have become available for clinical use. A recent phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab improved overall survival compared with sorafenib therapy. This article reviews recent advances in systemic therapy for HCC.